Eisai (OTCPK:ESAL.F) - Stock Price, News & Analysis

ESAL.F Stock Overview

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.

About the company

ESAL.F fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 26.9% below our estimate of its fair value

Earnings are forecast to grow 13.24% per year

Earnings grew by 70.1% over the past year

Risk Analysis

Dividend of 2.63% is not well covered by earnings or cash flows

Eisai Co., Ltd. Competitors

Royalty Pharma

NasdaqGS:RPRX

US$16.6b

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$6.8b

Taisho Pharmaceutical Holdings

OTCPK:TAIP.Y

US$4.3b

Organon

NYSE:OGN

US$4.7b

Price History & Performance

Summary of all time highs, changes and price drops for Eisai
Historical stock prices
Current Share Price	JP¥38.71
52 Week High	JP¥81.03
52 Week Low	JP¥37.53
Beta	-0.049
1 Month Change	-8.24%
3 Month Change	-16.66%
1 Year Change	-32.63%
3 Year Change	n/a
5 Year Change	-54.19%
Change since IPO	91.70%

Recent updates

Shareholder Returns

	ESAL.F	US Pharmaceuticals	US Market
7D	-0.7%	0.9%	1.2%
1Y	-32.6%	13.9%	24.7%

Return vs Industry: ESAL.F underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.

Return vs Market: ESAL.F underperformed the US Market which returned 19.3% over the past year.

Price Volatility

Is ESAL.F's price volatile compared to industry and market?
ESAL.F volatility
ESAL.F Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ESAL.F's share price has been volatile over the past 3 months.

Volatility Over Time: ESAL.F's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1941	11,076	Haruo Naito	www.eisai.co.jp

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.

Eisai Co., Ltd. Fundamentals Summary

How do Eisai's earnings and revenue compare to its market cap?
ESAL.F fundamental statistics
Market cap	US$11.28b
Earnings (TTM)	US$293.38m
Revenue (TTM)	US$4.84b

38.5x

P/E Ratio

2.3x

P/S Ratio

Is ESAL.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ESAL.F income statement (TTM)
Revenue	JP¥749.46b
Cost of Revenue	JP¥157.79b
Gross Profit	JP¥591.67b
Other Expenses	JP¥546.25b
Earnings	JP¥45.42b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 15, 2024

Earnings per share (EPS)	158.37
Gross Margin	78.95%
Net Profit Margin	6.06%
Debt/Equity Ratio	19.7%

How did ESAL.F perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

101%

Payout Ratio

ESAL.F Stock Overview

Rewards

Risk Analysis

Eisai Co., Ltd. Competitors

NasdaqGS:RPRX

US$16.6b

NasdaqGS:JAZZ

US$6.8b

OTCPK:TAIP.Y

US$4.3b

NYSE:OGN

US$4.7b

Price History & Performance

Recent News & Updates

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Recent updates

Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025

Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China

Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20

Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

Eisai Co., Ltd. Announces Dividend for the Second Quarter End of the Fiscal Year Ending March 31, 2024, Payable on November 17, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Eisai Co., Ltd., Annual General Meeting, May 22, 2024

NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others.

Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer

NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion.

Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma

Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea

Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. Announces Article About Long-Term Health Outcomes of Its Investigational Anti-Amyloid-Beta Protofibril Antibody Lecanemab in People Living

Eisai Co., Ltd. to Report Q2, 2023 Results on Nov 07, 2022

Eisai Co., Ltd. (TSE:4523) acquired an unknown minority stake in Arteryex Co., Ltd.

Eisai Co., Ltd. and Biogen Inc. Initiate A Submission to the Pharmaceuticals and Medical Devices Agency of Application Data Under the Prior Assessment Consultation System in Japan for the Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Biogen Inc. and Eisai Co., Ltd. Provides Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

Eisai Co., Ltd. Announces Dominantly Inherited Alzheimer Network Trials Unit Enrolls the First Subject in the Phase II/III Study

Biogen Inc. and Eisai Company, Ltd. Announces Japan’S Ndc of the Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains Under Review

Biogen Inc. and Eisai Co., Ltd. Announces Update on Regulatory Submission for Aducanumab in the European Union

Eisai Presents Final Results of Phase IV Elevate Study of Anti-Epileptic Drug FYCOMPA® (perampanel) at the American Epilepsy Society 2021 Annual Meeting

Eisai Co., Ltd. to Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting

Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022